Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iberdomide, Belantamab Mafodotin, and Dexamethasone in Relapsed Refractory Multiple Myeloma
NCT06232044Phase 2Suspended
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of iberdomide in multiple myeloma (MM) (3 arms), sponsored by Cancer and Leukemia Group B. Primary endpoints: Maximum Tolerated Dose at 28 days and Progression-Free Survival at 3 years. Started Apr 2025; status: suspended.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06232044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06232044.